Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals Inc    ARWR

ARROWHEAD PHARMACEUTICALS INC

(ARWR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:24pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On January 7, 2019, Arrowhead Pharmaceuticals, Inc. (the "Company") and Peter Leone, the Company's Vice President of Strategic Business Initiatives, entered into a separation agreement (the "Agreement") providing for severance payments as set forth below.

Mr. Leone's position with the Company is eliminated and pursuant to the Agreement he shall receive an amount equal to three month's salary from the Company and the Company shall accelerate the vesting of any unvested stock options granted to Mr. Leone during his employment with the Company.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARROWHEAD PHARMACEUTICALS
05/31ARROWHEAD PHARMACEUTICALS : to Present at Upcoming June 2019 Conferences
BU
05/20Arrowhead Shares Up, Orion Group Falls After Hours on S&P SmallCap 600 Moves
DJ
05/08ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
05/08ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
05/08ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2019 Second Quarter Results
BU
05/03ARROWHEAD PHARMACEUTICALS INC : half-yearly earnings release
05/02ARROWHEAD PHARMACEUTICALS : to Present at Upcoming May 2019 Conferences
BU
04/24ARROWHEAD PHARMACEUTICALS : to Webcast Fiscal 2019 Second Quarter Results
BU
04/24ARROWHEAD PHARMACEUTICALS : Begins Triple Combination Cohort in Chronic HBV Pati..
PU
04/19ARROWHEAD PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Cr..
AQ
More news
Financials ($)
Sales 2019 165 M
EBIT 2019 61,5 M
Net income 2019 67,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 39,78
P/E ratio 2020
Capi. / Sales 2019 15,5x
Capi. / Sales 2020 28,8x
Capitalization 2 565 M
Chart ARROWHEAD PHARMACEUTICALS INC
Duration : Period :
Arrowhead Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 28,1 $
Spread / Average Target 3,8%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Bruce D. Given Chief Operating Officer
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS INC112.96%2 314
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB13.49%10 857
SAREPTA THERAPEUTICS INC21.25%8 523